<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04436822</url>
  </required_header>
  <id_info>
    <org_study_id>CIP330</org_study_id>
    <nct_id>NCT04436822</nct_id>
  </id_info>
  <brief_title>Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics</brief_title>
  <official_title>Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Diabetes</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Diabetes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in&#xD;
      subjects age 2 - 80 years, for the span of 170 hours (7 days).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in&#xD;
      subjects age 2 - 80 years, for the span of 170 hours (7 days).&#xD;
&#xD;
      This is a multi-center study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">July 15, 2020</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>20% (±20 mg/dL [1.1 mmol/L] when SG less than (&lt;) 80 mg/dL [4.4 mmol/L]) Agreement, by age group and insertion location</measure>
    <time_frame>170 hours</time_frame>
    <description>Sensor values will be compared to YSI™* plasma glucose values during YSI™* FSTs. A within 20% mean agreement rate (±20 mg/dL [1.1 mmol/L] when SG less than (&lt;) 80 mg/dL [4.4 mmol/L]), µ, between sensor values and YSI™* plasma glucose values during YSI™* FST days will be evaluated.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">376</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Subjects with diabetes wearing DS5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects wearing DS5 over 7 days and participating in FSTs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Continuous Glucose Monitoring</intervention_name>
    <description>CGM and frequent sample testing</description>
    <arm_group_label>Subjects with diabetes wearing DS5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Individual is 2 - 80 years of age at time of enrollment.&#xD;
&#xD;
          2. Subject has a clinical diagnosis of type 1 or type 2 diabetes:&#xD;
&#xD;
               1. If subject is 14-80 years of age, subject has a clinical diagnosis of type 1 or&#xD;
                  type 2 diabetes for a minimum of 6 months duration as determined via medical&#xD;
                  record/ source documentation by an individual qualified to make a medical&#xD;
                  diagnosis.&#xD;
&#xD;
               2. If subject is 2-13 years of age, subject has a clinical diagnosis of type 1 or&#xD;
                  type 2 diabetes as determined via medical record/ source documentation by an&#xD;
                  individual qualified to make a medical diagnosis.&#xD;
&#xD;
          3. If subject is participating in YSI™* FST , subject has adequate venous access as&#xD;
             assessed by investigator or appropriate staff.&#xD;
&#xD;
          4. Subjects participating in the high and low glucose challenges must have an insulin&#xD;
             carbohydrate ratio(s) and insulin sensitivity factor(s). Subjects without ratios may&#xD;
             participate under observation only.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject will not tolerate tape adhesive in the area of sensor placement as assessed by&#xD;
             a qualified individual.&#xD;
&#xD;
          2. Subject has any unresolved adverse skin condition in the area of sensor or device&#xD;
             placement (e.g., psoriasis, rash, Staphylococcus infection).&#xD;
&#xD;
          3. Subject is actively participating in an investigational study (e.g., drug or device)&#xD;
             wherein he/she has received treatment from an investigational study (drug or device)&#xD;
             in the last 2 weeks prior to Visit 1. (Please note participation in an observational&#xD;
             study is acceptable.)&#xD;
&#xD;
          4. Subject is female of child-bearing potential and has a pregnancy screening test that&#xD;
             is positive.&#xD;
&#xD;
          5. Subject is a sexually active female of child-bearing potential and is not using a form&#xD;
             of contraception deemed reliable by investigator.&#xD;
&#xD;
          6. Subject is female and plans to become pregnant during the course of the study.&#xD;
&#xD;
          7. Subject has had a hypoglycemic seizure within the past 6 months prior to enrollment.&#xD;
&#xD;
          8. Subject has had hypoglycemia resulting in loss of consciousness within the past 6&#xD;
             months prior to enrollment.&#xD;
&#xD;
          9. Subject has had an episode of diabetic ketoacidosis (DKA) within the past 6 months&#xD;
             prior to enrollment.&#xD;
&#xD;
         10. Subject has a history of a seizure disorder.&#xD;
&#xD;
         11. Subject has central nervous system or cardiac disorder resulting in syncope.&#xD;
&#xD;
         12. Subject has a history of myocardial infarction, unstable angina, coronary artery&#xD;
             bypass surgery, coronary artery stenting, transient ischemic attack (TIA),&#xD;
             cerebrovascular accident (CVA), angina, congestive heart failure, ventricular rhythm&#xD;
             disturbances or thromboembolic disease&#xD;
&#xD;
         13. If subject is 7-80 years of age, subject has a hematocrit (Hct) more than 10% below&#xD;
             the lower limit of normal reference range (please note that patients may use prior&#xD;
             blood draw from routine care as long as done within 6 months of screening and report&#xD;
             of lab placed with subject source documents).&#xD;
&#xD;
         14. Subject has a history of adrenal insufficiency.&#xD;
&#xD;
         15. Subject is a member of the research staff involved with the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>AMCR Institute</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sansum Diabetes Research Institute</name>
      <address>
        <city>Santa Barbara</city>
        <state>California</state>
        <zip>93105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SoCal Diabetes</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diablo Clinical Research, Inc.</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Childhood Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barbara Davis Center for Diabetes</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta Diabetes Associates</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30318</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rocky Mountain Diabetes and Osteoporosis Center</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AM Diabetes and Endocrinology Center</name>
      <address>
        <city>Bartlett</city>
        <state>Tennessee</state>
        <zip>38133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78749</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Center for Diabetes Technology</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rainier Clinical Research Center, Inc.</name>
      <address>
        <city>Renton</city>
        <state>Washington</state>
        <zip>98057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 12, 2020</study_first_submitted>
  <study_first_submitted_qc>June 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

